Table 1 Estimated IQ and economic loss attributable to blood lead levels above 20 μg/L: Estimates per 100,000 individuals in FLEHSI, FLEHSII, and FLEHSIII as assessed by the linear-log and the linear-interval dose response relationship
Dose Response Relationship | Study – Sampling period | Proportion population B-Pb > = 20 μg/L (%) | Average IQ-loss per individual (points) with B-Pb ≥ 20 μg/L | IQ-loss per 100,000 individuals (points) attributable to B-Pb ≧ 20 μg/La | Cost per 100,000 individuals attributable to B-Pb ≧ 20 μg/L (106 EUR)a,b |
|---|---|---|---|---|---|
Linear-log | FLEHSI 2003–2004 | 56.62 | 1.67 (95% CI:1.03–2.3) | 94,280 (95% CI: 58,427-130,138) | 1835 (95% CI: 1137-2533) |
FLEHSII 2008–2009 | 22.79 | 0.66 (95% CI:0.41–0.91) | 14,993 (95% CI: 9289-20,695) | 292 (95% CI: 181–403) | |
FLEHSIII 2013–2014 | 2.50 | 0.39 (95% CI:0.24–0.54) | 976 (95% CI: 604–1347) | 19 (95% CI: 12–26) | |
Sensitivity analysis: Linear-interval | FLEHSI 2003–2004 | 56.62 | 1.14 (95% CI:0.71–1.57) | 64,421 (95% CI: 39,923-88,913) | 1254 (95% CI: 777–1731) |
FLEHSII 2008–2009 | 22.79 | 0.33 (95% CI:0.2–0.46) | 7539 (95% CI: 4672–10,404) | 147 (95% CI: 91–203) | |
FLEHSIII 2013–2014 | 2.50 | 0.18 (95% CI:0.11–0.25) | 451 (95% CI: 279–622) | 9 (95% CI: 5–12) |